Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) rose 2.4% during trading on Wednesday . The company traded as high as $5.12 and last traded at $4.78. Approximately 1,713,600 shares changed hands during trading, an increase of 13% from the average daily volume of 1,510,882 shares. The stock had previously closed at $4.90.

KERX has been the topic of a number of analyst reports. Maxim Group reaffirmed a “buy” rating and set a $9.00 target price on shares of Keryx Biopharmaceuticals in a report on Thursday, July 20th. Cowen and Company reaffirmed a “market perform” rating on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. BidaskClub cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Morgan Stanley reissued an “equal weight” rating and set a $7.00 price target (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Finally, ValuEngine raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $7.35.

The company has a quick ratio of 3.76, a current ratio of 4.46 and a debt-to-equity ratio of 13.95.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative net margin of 323.92% and a negative return on equity of 10,954.62%. The firm had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. During the same period in the prior year, the firm earned ($0.39) EPS. Keryx Biopharmaceuticals’s revenue for the quarter was up 138.1% compared to the same quarter last year. research analysts forecast that Keryx Biopharmaceuticals, Inc. will post -1.36 earnings per share for the current year.

Large investors have recently modified their holdings of the business. Fox Run Management L.L.C. purchased a new position in Keryx Biopharmaceuticals during the third quarter valued at approximately $101,000. Engineers Gate Manager LP purchased a new position in Keryx Biopharmaceuticals during the third quarter valued at approximately $102,000. Principal Financial Group Inc. lifted its holdings in Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 590 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in Keryx Biopharmaceuticals by 51.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 5,628 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Keryx Biopharmaceuticals in the second quarter worth $183,000. 65.44% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Keryx Biopharmaceuticals, Inc. (KERX) Stock Price Up -2.4%” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://theolympiareport.com/2017/11/17/keryx-biopharmaceuticals-inc-kerx-stock-price-up-2-4.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.